The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients in the reboxetine plus celecoxib group exhibited reductions in depression severity that were nearly twice as great (55% reduction) as those experienced by patients in the control group (33% reduction).”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“One study found positive effects on mood in medically healthy, major depressed patients.52”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [52]
In the citing paper
“from the administration of COX2 inhibitors to patients with major depression81”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [81]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The global burden of disease, 1990–2020
Lopez, A. D., & Murray, C. C. J. L. (1998) · Nature Medicine · doi:10.1038/3218 · Cited by 1,614
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 236
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Cited by
Items 201–300 of 802
Arabzadeh, S., Ameli, N., Zeinoddini, A., Rezaei, F., Farokhnia, M., Mohammadinejad, P., Ghaleiha, A., & Akhondzadeh, S. (2015) · Bipolar Disorders · doi:10.1111/bdi.12324 · Cited by 98
Treatment-Resistant Depression Revisited: A Glimmer of Hope
Halaris, A. E., Sohl, E., & Whitham, E. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020155 · Cited by 110
The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration
Wang, Z., Zhang, Q., Yuan, L., Wang, S., Liu, L., Yang, X., Li, G., & Liu, D. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.018 · Cited by 110
Lu, S., Peng, H., Wang, L., Seewoobudul, V., Zhang, Y., Gao, W., Wu, W., Liao, M., Wang, M., Tang, H., et al. (2013) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2013.03.026 · Cited by 109
Chen, Y., Zhang, Y., Wang, J., Li, S., Wang, Y., Zhang, Z., Zhang, J., Xin, C., Wang, Y., & Rong, P. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14207 · Cited by 106
Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing
El‐Malah, A., Gineinah, M. M., Deb, P. K., Khayyat, A. N., Bansal, M., Venugopala, K. N., & Aljahdali, A. S. (2022) · Pharmaceuticals · doi:10.3390/ph15070827 · Cited by 106
Liu, H., Luiten, P. G. M., Eisel, U. L. M., DeJongste, M. J. L., & Schoemaker, R. G. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.02.004 · Cited by 101
Inserra, A., Mastronardi, C. A., Rogers, G., Licinio, J., & Wong, M.-L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1359-3 · Cited by 96
Research Review: The role of cytokines in depression in adolescents: a systematic review
Mills, N. T., Scott, J. G., Wray, N. R., Cohen‐Woods, S., & Baune, B. T. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12080 · Cited by 92
Identification and treatment of symptoms associated with inflammation in medically ill patients
Dantzer, R., Capuron, L., Irwin, M. R., Miller, A. H., Ollat, H., Perry, V. H., Rousey, S., & Yirmiya, R. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.10.008 · Cited by 110
Fields, C., Drye, L., Vaidya, V., & Lyketsos, C. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318227f4da · Cited by 96
Nierenberg, A. A., Ghaznavi, S., Mathias, I. S., Ellard, K. K., JANOS, J. A., & Sylvia, L. G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.014 · Cited by 100
The effects of apigenin on lipopolysaccharide-induced depressive-like behavior in mice
Li, R., Zhao, D., Qu, R., Fu, Q., & Ma, S. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.040 · Cited by 100
Anderson, G., Berk, M., Dean, O., Moylan, S., & Maes, M. (2014) · CNS Drugs · doi:10.1007/s40263-013-0119-1 · Cited by 94
Personalized medicine in psychiatry
Wium-Andersen, I. K., Vinberg, M., Kessing, L. V., & McIntyre, R. S. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2016.1216163 · Cited by 74
Mind, Mood and Microbiota—Gut–Brain Axis in Psychiatric Disorders
Toader, C., Dobrin, N., Costea, D., Glavan, L.-A., Covache-Busuioc, R.-A., Dumitrascu, D.-I., Bratu, B.-G., Costin, H. P., & Ciurea, A. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063340 · Cited by 106
Immune-based strategies for mood disorders: facts and challenges
Colpo, G. D., Leboyer, M., Dantzer, R., Trivedi, M. H., & Teixeira, A. L. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1407242 · Cited by 89
Increased soluble tumor necrosis factor‐α receptors in patients with major depressive disorder
Grassi‐Oliveira, R., Brietzke, E., Pezzi, J. C., Lopes, R. P., Teixeira, A. L., & Bauer, M. E. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01918.x · Cited by 92
Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans
Bershad, A. K., Miller, M. A., Norman, G. J., & de Wit, H. (2018) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.04.009 · Cited by 97
Advanced Glycation and Lipoxidation End Products–Amplifiers of Inflammation: The Role of Food
Bengmark, S. (2007) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607107031005430 · Cited by 100
Müller, N., Myint, A.-M., & Schwarz, M. J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/nmueller · Cited by 93
Self-citationCommon mechanisms of pain and depression: are antidepressants also analgesics?
Nekovářová, T., Yamamotová, A., Valeš, K., Stuchlík, A., Fricová, J., & Rokyta, R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00099 · Cited by 101
Stress-Related Immune Markers in Depression: Implications for Treatment
Hughes, M. M., Connor, T. J., & Harkin, A. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw001 · Cited by 85
Sethi, R., Gómez‐Coronado, N., Walker, A. J., Robertson, O. D., Agustini, B., Berk, M., & Dodd, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00605 · Cited by 100
Reyes-Gibby, C. C., Wang, J., Spitz, M., Wu, X., Yennurajalingam, S., & Shete, S. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.07.019 · Cited by 88
Dean, B. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001410 · Cited by 88
Geller, D. A., Homayoun, S., & Johnson, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.678538 · Cited by 89
Faridhosseini, F., Sadeghi, R., Farid, L., & Pourgholami, M. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2401 · Cited by 89
Application of antidepressants in depression: A systematic review and meta-analysis
Yuan, Z., Chen, Z., Xue, M., Zhang, J., & Leng, L. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.08.013 · Cited by 94
Role of Inflammation in Depression: Implications for Phenomenology, Pathophysiology and Treatment
Raison, C. L., & Miller, A. H. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343966 · Cited by 88
Goldstein, B. I., & Young, L. T. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0425-9 · Cited by 84
Tang, M., Liu, T., Jiang, P., & Dang, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105586 · Cited by 88
Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis
Pastis, I., Santos, M. G., & Paruchuri, A. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1282242 · Cited by 103
Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression
Phillips, C., & Fahimi, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00498 · Cited by 81
Vollmar, P., Nessler, S., Kalluri, S. R., Hartung, H.-P., & Hemmer, B. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009425 · Cited by 87
Altered Serum Levels of TNF-α, IL-6, and IL-18 in Depressive Disorder Patients
Fan, N., Luo, Y., Ou, Y., & He, H. (2017) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2588 · Cited by 85
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Wang, Q., Yang, C., Gelernter, J., & Zhao, H. (2015) · Human Genetics · doi:10.1007/s00439-015-1596-8 · Cited by 83
Microglia activation is associated with IFN-α induced depressive-like behavior
Wachholz, S., Eßlinger, M., Plümper, J., Manitz, M. P., Juckel, G., & Friebe, A. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.09.016 · Cited by 92
Neuroinflammatory basis of depression: learning from experimental models
Afridi, R., & Suk, K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.691067 · Cited by 82
Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases
Beurel, E. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00018 · Cited by 82
The role of anti-inflammatory treatment in psychiatric disorders.
Müller, N. (2013) · PubMed · Cited by 95
Self-citationPucak, M. L., Carroll, K. A. L., Kerr, D. A., & Kaplin, A. L. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.2/mpucak · Cited by 89
Geng, J., Liu, J., Yuan, X., Liu, W., & Guo, W. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114688 · Cited by 85
Glia in the cytokine-mediated onset of depression: fine tuning the immune response
Jo, W. K., Zhang, Y., Emrich, H. M., & Dietrich, D. E. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00268 · Cited by 77
Millan, M. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001496 · Cited by 79
The role of inflammatory cytokines on the aetiopathogenesis of depression
Makhija, K., & Karunakaran, S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413488220 · Cited by 76
Rapoport, S. I. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500058v · Cited by 78
Gill, J., Luckenbaugh, D., Charney, D., & Vythilingam, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.033 · Cited by 80
Lim, J., Bang, Y., & Choi, H. J. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1063-x · Cited by 85
Fiore, N. T., & Austin, P. J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.04.012 · Cited by 88
Immunological aspects of the treatment of depression and schizophrenia
Müller, N. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/nmueller · Cited by 85
Self-citationŚliwiński, T. (2015) · Medical Science Monitor · doi:10.12659/msm.892317 · Cited by 78
“Moreover, it was shown that anti-inflammatory drugs act as antidepressants, and medication used in DD therapy has anti-inflammatory effects [11-14].”
BackgroundHlavacova, N., Wes, P. D., Ondrejcakova, M., Flynn, M. E., Poundstone, P. K., Babic, S., Murck, H., & Jezova, D. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000368 · Cited by 74
Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications
Su, K. (2012) · Biomedicine · doi:10.1016/j.biomed.2012.03.002 · Cited by 81
Novel Pharmacological Approaches to the Treatment of Depression
Elias, E., Zhang, A. Y., & Manners, M. T. (2022) · Life · doi:10.3390/life12020196 · Cited by 90
Rahimian, R., Belliveau, C., Chen, R., & Mechawar, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.871997 · Cited by 87
Koeberle, A., Rossi, A., Bauer, J., Dehm, F., Verotta, L., Northoff, H., Sautebin, L., & Werz, O. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00007 · Cited by 88
Inflammation and depression but where does the inflammation come from?
Halaris, A. E. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000531 · Cited by 80
Müller, N., Krause, D., Barth, R., Myint, A.-M., Weidinger, E., Stettinger, W., Zill, P., Drexhage, H., & Schwarz, M. J. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.088 · Cited by 72
Self-citationThe inflammatory underpinning of depression: An historical perspective
Yirmiya, R. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.08.048 · Cited by 87
LOTRICH, F. E., EL-GABALAWY, H., GUENTHER, L. C., & WARE, C. F. (2011) · The Journal of Rheumatology Supplement · doi:10.3899/jrheum.110903 · Cited by 75
The hidden third: improving outcome in treatment-resistant depression
Schlaepfer, T. E., Ågren, H., Monteleone, P., Gasto, C., Pitchot, W., Rouillon, F., Nutt, D. J., & Kasper, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431748 · Cited by 74
The impact of stress on immune systems and its relevance to mental illness
Ishikawa, Y., & Furuyashiki, T. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.09.005 · Cited by 78
Poon, D. C.-H., Ho, J. Y. S., Chiu, K., Wong, H.-L., & Chang, R. C. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.015 · Cited by 84
Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells
Nahman, S., Belmaker, R., & Azab, A. N. (2012) · Innate Immunity · doi:10.1177/1753425911421512 · Cited by 72
Savitz, J., Preskorn, S., Teague, T. K., Drevets, D., Yates, W., & Drevets, W. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000643 · Cited by 73
Stapel, B., Sieve, I., Falk, C. S., Bleich, S., Hilfiker‐Kleiner, D., & Kahl, K. G. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.017 · Cited by 84
Wang, J.-M., Yang, L.-H., Zhang, Y.-Y., Niu, C.-L., Cui, Y., Feng, W.-S., & Wang, G.-F. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.08.008 · Cited by 72
Phillips, C. (2017) · Neural Plasticity · doi:10.1155/2017/7014146 · Cited by 65
Chronic intermittent cold stress sensitizes neuro-immune reactivity in the rat brain
Girotti, M., Donegan, J. J., & Morilak, D. A. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.02.008 · Cited by 70
Grosse, L., Carvalho, L. A., Wijkhuijs, A. J. M., Bellingrath, S., Ruland, T., Ambrée, O., Alferink, J., Ehring, T., Drexhage, H. A., & Arolt, V. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.08.004 · Cited by 71
“Also the anti-inflammatory cyclooxygenase-2 (COX-2) inhibitor celecoxib exhibited a therapeutic effect in major depression in a randomized, placebo controlled trial (Muller et al., 2006).”
Self-citationAre there meaningful biomarkers of treatment response for depression?
Breitenstein, B., Scheuer, S., & Holsboer, F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.002 · Cited by 74
The significance of routine biochemical markers in patients with major depressive disorder
Peng, Y.-F., Xiang, Y., & Wei, Y.-S. (2016) · Scientific Reports · doi:10.1038/srep34402 · Cited by 70
Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders
Müller, N., & Schwarz, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.1017 · Cited by 77
Self-citationWang, H., Hai, S., Liu, Y., Li, C., Liu, Y., Liu, P., Zhou, J., Yang, Y., & Dong, B. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s173146 · Cited by 67
Antidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression
Hwang, E., Kim, H.-B., Lee, S., Kim, M. J., Kim, K.-J., Han, G., Han, S.-Y., Lee, E.-A., Yoon, J.-H., Kim, D., et al. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112439 · Cited by 76
Xie, Z., Huang, J., Sun, G., He, S., Luo, Z., Zhang, L., Li, L., Yao, M., Du, C., Yu, W., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115804 · Cited by 74
Hamdani, N., Daban, C., Lajnef, M., Gadel, R., Corvoisier, P. L., Delavest, M., Carde, S., Lépine, J., Jamain, S., Houenou, J., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.038 · Cited by 67
Li, X., Huan, J.-M., Lin, L., & Hu, Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1097196 · Cited by 80
Lee, S., Kim, H.-B., Hwang, E., Kim, E.-S., Kim, S. S., Jeon, T.-D., Song, M.-C., Lee, J.-S., Chung, M.-C., Maeng, S., et al. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.3.189 · Cited by 71
Fourrier, C., Sampson, E., Mills, N. T., & Baune, B. T. (2018) · Trials · doi:10.1186/s13063-018-2829-7 · Cited by 65
Brain-immune crosstalk in the treatment of major depressive disorder
Branchi, I., Poggini, S., Capuron, L., Benedetti, F., Poletti, S., Tamouza, R., Drexhage, H. A., Penninx, B. W. J. H., & Pariante, C. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.016 · Cited by 64
Chang, C.-C., Tzeng, N.-S., Kao, Y.-C., Yeh, C.-B., & Chang, H.-A. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.076 · Cited by 65
Mind and body: how the health of the body impacts on neuropsychiatry
Renoir, T., Hasebe, K., & Gray, L. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00158 · Cited by 72
Neuroscience-driven discovery and development of sleep therapeutics
Dresler, M., Spoormaker, V. I., Beitinger, P., Czisch, M., Kimura, M., Steiger, A., & Holsboer, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.012 · Cited by 63
Köhler‐Forsberg, O., Petersen, L. V., Mors, O. N., & Gasse, C. (2015) · Brain and Behavior · doi:10.1002/brb3.338 · Cited by 66
Li, Y., Shen, J.-D., Li, J., Wang, R., Jiao, S., & Yi, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.09.007 · Cited by 64
Cytokine Genes TNF, IL1A, IL1B, IL6, IL1RN and IL10, and Childhood-Onset Mood Disorders
Misener, V. L., Gomez, L., Wigg, K. G., Luca, P., King, N., Kiss, E., Daróczi, G., Kapornai, K., Tamas, Z., Mayer, L., et al. (2008) · Neuropsychobiology · doi:10.1159/000159775 · Cited by 61
Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.07.092 · Cited by 62
Mousavi, S. Y., Khezri, R., Karkhaneh-Yousefi, M.-A., Mohammadinejad, P., Gholamian, F., Mohammadi, M. R., Zeinoddini, A., & Akhondzadeh, S. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0207 · Cited by 61
Regulska, M., Szuster-Głuszczak, M., Trojan, E., Leśkiewicz, M., & Basta‐Kaim, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200807144530 · Cited by 67
Sex-Dependent Effects of Neonatal Inflammation on Adult Inflammatory Markers and Behavior
Kentner, A. C., McLeod, S. A., Field, E. F., & Pittman, Q. J. (2010) · Endocrinology · doi:10.1210/en.2009-1101 · Cited by 59
Molecular Neurobiology and Promising New Treatment in Depression
Jeon, S. R., & Kim, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030381 · Cited by 73
Neuroimmune and Inflammatory Signals in Complex Disorders of the Central Nervous System
Liberman, A. C., Trías, E., Chagas, L. D. S., Trindade, P., Pereira, M. D. S., Refojo, D., Hedin‐Pereira, C., & Serfaty, C. A. (2018) · NeuroImmunoModulation · doi:10.1159/000494761 · Cited by 66
Wang, H., Tian, X., Wang, X., & Wang, Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.705749 · Cited by 68
Microglial Responses to Stress-Induced Depression: Causes and Consequences
Afridi, R., & Suk, K. (2023) · Cells · doi:10.3390/cells12111521 · Cited by 69
Antidepressant and Antioxidative Effect of Ibuprofen in the Rotenone Model of Parkinson’s Disease
Zaminelli, T., Gradowski, R. W., Bassani, T. B., Barbiero, J. K., Santiago, R. M., Ferreira, D. M., Baggio, C. H., & Vital, M. A. B. F. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9467-y · Cited by 61
Edberg, D., Hoppensteadt, D., Walborn, A., Fareed, J., Sinacore, J., & Halaris, A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.02.004 · Cited by 60
Attwells, S., Setiawan, E., Rusjan, P., Xu, C., Hutton, C., Rafiei, D., Varughese, B., Kahn, A., Kish, S. J., Vasdev, N., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.03.007 · Cited by 64
Metadata
- Authors
- Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.-J., Arolt, V, & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Münster (DE)
- Corresponding author
- Müller, N
- Venue
- Molecular Psychiatry
- Published
- 2006-02-21
- Volume
- 11
- Issue
- 7
- Pages
- 680-684
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2049808835
- Cited by
- 794
- References
- 37
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 44 · 2018: 52 · 2017: 45 · 2016: 42 · 2015: 54 · 2014: 53 · 2013: 61 · 2012: 50
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- celecoxib, COX-2 inhibitors, major depressive disorder, reboxetine, anti-inflammatory therapy, inflammatory cytokines, prostaglandin E2, adjunctive therapy, acute depressive episode
- MeSH terms
- Celecoxib, Reboxetine, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation, Lorazepam, Male, Middle Aged, Morpholines, Patient Dropouts, Pilot Projects, Psychological Tests, Pyrazoles, Serotonin, Severity of Illness Index, Sulfonamides, Anti-Anxiety Agents, Dinoprostone, Interleukin-6, Adrenergic Uptake Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.